GlassScriptPhysician profile
Raymond Everett Lewis
NPI 1861488538
$9,660.77
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,475 · 2020: $1,206 · 2021: $1,886 · 2022: $2,437 · 2023: $1,964 · 2024: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,656.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,554.71 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,448.69 | 2019-2024 | Breztri, Fasenra, Airsupra |
| Actelion Pharmaceuticals US, INC. | $1,208.17 | 2019-2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,121.71 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Genzyme Corporation | $740.71 | 2019-2024 | |
| Insmed, INC. | $637.70 | 2019-2024 | Arikayce |
| United Therapeutics Corporation | $598.08 | 2019-2024 | Tyvaso |
| Mylan Specialty L.P. | $511.65 | 2019-2024 | Yupelri |
| Gilead Sciences, INC. | $412.43 | 2021-2024 | Veklury |
| Merck Sharp & Dohme LLC | $229.09 | 2019-2024 | Winrevair, Zerbaxa, Recarbrio |
| Amgen INC. | $193.16 | 2022-2024 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $125.93 | 2021-2024 | Dupixent |
| Grifols USA, LLC | $104.03 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.81 | 2019-2023 | |
| Electromed, INC. | $79.49 | 2023 | Smartvest |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $78.22 | 2020-2024 | Glassia |
| Harmony Biosciences LLC | $74.01 | 2021-2024 | Wakix |
| Alexion Pharmaceuticals, INC. | $67.86 | 2019-2022 | |
| Philips North America LLC | $55.65 | 2019 | |
| Advanced Respiratory, INC | $54.78 | 2020-2021 | |
| Genentech USA, INC. | $37.41 | 2020-2023 | Xolair |
| Resmed Corp | $32.81 | 2021 | |
| Baxter Healthcare | $32.02 | 2023 | Hillrom - Life 2000 Ventilation System |
| Fisher & Paykel Healthcare INC | $23.71 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.43 | 2019 | |
| Portola Pharmaceuticals, LLC | $22.51 | 2020 | |
| Ekos Corporation | $19.47 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.76 | 2019 | |
| Circassia INC. | $14.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.47 | 2021 | |
| Olympus America INC. | $13.12 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.